发明名称 |
MITOCHONDRIAL TARGETING AND THERAPEUTIC USE THEREOF |
摘要 |
The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry. |
申请公布号 |
US2016237129(A1) |
申请公布日期 |
2016.08.18 |
申请号 |
US201614993500 |
申请日期 |
2016.01.12 |
申请人 |
Shire Human Genetic Therapies, Inc. |
发明人 |
Keefe Dennis;Concino Michael;Heartlein Michael;Josiah Serene;Strack-Logue Bettina |
分类号 |
C07K14/47 |
主分类号 |
C07K14/47 |
代理机构 |
|
代理人 |
|
主权项 |
1. A targeted therapeutic comprising
a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus and an amino acid sequence at least 80% identical to mature human Frataxin protein (SEQ ID N0:1); a mitochondrial targeting sequence; and a mitochondrial membrane-penetrating peptide, wherein the mitochondrial targeting sequence is associated with the N-terminus of the therapeutic moiety and the mitochondrial membrane-penetrating peptide is associated with the C-terminus of the therapeutic moiety, and further wherein the therapeutic moiety is targeted to mitochondrial upon cellular entry. |
地址 |
Lexington MA US |